AstraZeneca extended survival signals in lung cancer through a combination outcome involving Tagrisso and Hutchmed’s Orpathys, according to a deal-and-pipeline roundup. In parallel, AstraZeneca also moved to cancel a Phase 3 lung cancer study of volrustomig after an interim data check suggested survival goals were unlikely to be met. The mixed oncology calendar highlights a pattern biotech readers recognize: companies are simultaneously investing in late-stage bets showing separation and trimming programs when endpoints look constrained. Together, the updates inform how sponsors may reshape development portfolios ahead of key regulatory milestones. For clinical strategists, the key follow-up is how AstraZeneca and partners will prioritize next-line study designs and what the volrustomig discontinuation means for similar target combinations.